C. Hulin

P. Moreau, L. Planche, C. Touzeau, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma.

B. Pégourié, O. Decaux, C. Sebban, 2011, Blood.

Bortezomib, Lenalidomide, and Dexamethasone (VRD) Consolidation and Lenalidomide Maintenance in Frontline Multiple Myeloma Patients: Updated Results of the IFM 2008 Phase II VRD Intensive Program

B. Pégourié, P. Moreau, H. Avet-Loiseau, 2011 .

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.

T. Willis, B. Pégourié, P. Richardson, 2018, Blood.

Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients

B. Pégourié, C. Sebban, P. Moreau, 2014, Leukemia.

Pharmacokinetic, Pharmacodynamic and Covariate Analysis of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma

D. Esseltine, K. Venkatakrishnan, P. Moreau, 2012, Clinical Pharmacokinetics.

Cytogenetic and therapeutic characterization of primary plasma cell leukemia: the IFM experience

P. Cony-Makhoul, O. Decaux, H. Avet-Loiseau, 2012, Leukemia.

Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison.

H. Goldschmidt, P. Sonneveld, P. Moreau, 2020, Immunotherapy.

myeloma autologous stem cell transplantation in newly diagnosed multiple thalidomide plus dexamethasone as induction treatment before Bortezomib plus dexamethasone versus reduced-dose bortezomib,

O. Decaux, C. Sebban, P. Moreau, 2012 .

Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma

O. Decaux, P. Moreau, H. Avet-Loiseau, 2021, Leukemia.

Three Drug Combinations in the Treatment of Fit Elderly Multiple Myeloma Patients

X. Leleu, J. Torregrosa, C. Hulin, 2020, Journal of clinical medicine.

A Frailty Scale Predicts Outcomes of Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone on the First Trial

M. Dimopoulos, M. Mohty, A. Belch, 2015 .

Clinical Characteristics, Chromosomal Abnormalities and Outcomes in Very Elderly Patients with Multiple Myeloma: The IFM Experience

B. Pégourié, O. Decaux, P. Moreau, 2012 .

Living with the burden of relapse in multiple myeloma from the patient and physician perspective.

K. Ramasamy, A. Tinel, Sue Perkins, 2017, Leukemia research.

Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results.

B. Pégourié, O. Decaux, P. Moreau, 2015, Blood.

Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.

B. Pégourié, O. Decaux, P. Moreau, 2013, Blood.

Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial

O. Decaux, A. Duhamel, P. Moreau, 2019, Clinical Cancer Research.

Phase 1/2 study of car ﬁ lzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma

J. Mary, P. Moreau, H. Avet-Loiseau, 2015 .

High Complete and Very Good Partial Response Rates with Bortezomib—Dexamethasone as Induction Prior to ASCT in Newly Diagnosed Patients with High-Risk Myeloma: Results of the IFM2005-01 Phase 3 Trial.

P. Moreau, H. Avet-Loiseau, G. Marit, 2009 .

Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA

H. Goldschmidt, O. Decaux, M. Mohty, 2022, Leukemia.

Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial.

J. Laubach, S. Iida, H. Nahi, 2020, The Lancet. Haematology.

Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma

B. Pégourié, O. Decaux, P. Moreau, 2015, Annals of Hematology.

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.

S. Lonial, S. Trudel, P. Richardson, 2019, The Lancet. Oncology.

Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma

P. Moreau, X. Leleu, J. Harousseau, 2008, Haematologica.

Efficacy of daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) in transplant-eligible newly diagnosed multiple myeloma (TE NDMM) based on minimal residual disease (MRD) status: Analysis of the CASSIOPEIA trial.

P. Sonneveld, M. Béné, P. Moreau, 2019, Journal of Clinical Oncology.

Integrated Analysis of Randomized Controlled Trials Evaluating Bortezomib + Lenalidomide + Dexamethasone or Bortezomib + Thalidomide + Dexamethasone Induction in Transplant-Eligible Newly Diagnosed Multiple Myeloma

A. Oriol, P. Moreau, M. Macro, 2018, Blood.

Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.

Sin-Ho Jung, A. Palumbo, P. Richardson, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 2 Study of 2 Modalities of Pomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma. IFM 2009-02

B. Pégourié, A. Duhamel, P. Moreau, 2010 .

Comparison of reduced-dose bortezomib plus thalidomide plus dexamethasone (vTD) to bortezomib plus dexamethasone (VD) as induction treatment prior to ASCT in de novo multiple myeloma (MM): Results of IFM2007-02 study.

P. Moreau, H. Avet-Loiseau, G. Marit, 2010 .

[Granulocyte sarcoma of the pancreas without extra-pancreatic location].

P. Feugier, E. Labouyrie, P. Lederlin, 2002, Presse medicale.

Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA)

H. Goldschmidt, Shaji K. Kumar, T. Plesner, 2018, Blood.

Autologous Transplantation for Multiple Myeloma in the Era of New Drugs: A Phase III Study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 Trial)

N. Munshi, P. Richardson, P. Moreau, 2015 .

Low‐dose vs. high‐dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myélome

B. Pégourié, I. Yakoub-Agha, M. Mohty, 2012, European journal of haematology.

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial

B. Pégourié, B. Grosbois, I. Yakoub-Agha, 2007, The Lancet.

The Translocation t(4;14) Can Be Present Only in Minor Subclones in Multiple Myeloma

P. Moreau, H. Avet-Loiseau, X. Leleu, 2013, Clinical Cancer Research.

Minor clone provides a reservoir for relapse in multiple myeloma

N. Munshi, O. Decaux, P. Moreau, 2013, Leukemia.

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

H. Goldschmidt, G. Morgan, A. Palumbo, 2012, Leukemia.

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

H. Goldschmidt, G. Morgan, A. Palumbo, 2012, Leukemia.

Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.

R. Bataille, B. Grosbois, I. Yakoub-Agha, 2007, Blood.

Updated Analysis of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): The Phase 3 Maia Study

H. Goldschmidt, Shaji K. Kumar, T. Plesner, 2020 .

[Pulmonary involvement with a favorable course during Loa loa filariasis].

C. Hulin, C. Rabaud, T. May, 1994, Bulletin de la Societe de pathologie exotique.

Single versus double autologous stem-cell transplantation for multiple myeloma.

R. Bataille, R. Bouabdallah, B. Grosbois, 2003, The New England journal of medicine.

Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma.

J. Bourhis, I. Yakoub-Agha, P. Moreau, 2006, Blood.

Daratumumab (DARA) with Bortezomib, Thalidomide, and Dexamethasone (VTd) in Transplant-Eligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) Negativity in Cassiopeia Part 1 and Part 2

P. Sonneveld, V. V. D. van der Velden, M. Mohty, 2021, Blood.

Daratumumab Plus Ixazomib, Lenalidomide, and Dexamethasone As Extended Induction and Consolidation Followed By Lenalidomide Maintenance in Standard-Risk Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (IFM 2018-01): A Phase II Study of the Intergroupe Francophone Du Myélome (IFM

O. Decaux, P. Moreau, H. Avet-Loiseau, 2021, Blood.

Improved survival in multiple myeloma during the 2005–2009 and 2010–2014 periods

M. Mohty, P. Moreau, H. Avet-Loiseau, 2021, Leukemia.

Cost and efficacy of peripheral stem cell mobilization strategies in multiple myeloma

J. Bourhis, P. Moreau, M. Macro, 2020, Bone Marrow Transplantation.

Frontline treatment in elderly patients with multiple myeloma.

J. S. San Miguel, T. Facon, M. Mateos, 2009, Seminars in hematology.

Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma.

B. Pégourié, O. Decaux, P. Moreau, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

High Response Rates to Pomalidomide and Dexamethasone in Patients with Refractory Myeloma, Final Analysis of IFM 2009-02

B. Pégourié, O. Decaux, P. Moreau, 2011 .

Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study.

Jean-Michel Nguyen, Caroline Bodet-Milin, Kenneth Anderson, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab

R. Vij, D. Atanackovic, P. Moreau, 2021, Blood Cancer Journal.

Four-Year Interim Analysis of Miroir, a French Multicenter, Non-Interventional Study of Pomalidomide in Relapsed/Refractory Multiple Myeloma

O. Decaux, M. Mohty, P. Moreau, 2019, Blood.

Pomalidomide Plus Low-Dose Dexamethasone In Relapsed Or Refractory Multiple Myeloma (RRMM) With Deletion (del)17p and/Or Translocation t(4;14)

B. Pégourié, O. Decaux, P. Moreau, 2013 .

elderly multiple myeloma patients ineligible for high-dose therapy Dexamethasone-based regimens versus melphalan-prednisone for

J. Rossi, R. Bataille, I. Yakoub-Agha, 2011 .

Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy

Augustin Ferrant, Chantal Doyen, J. Rossi, 2006 .

Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study.

B. Pégourié, P. Moreau, H. Avet-Loiseau, 2006, Haematologica.

Comparative efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) without and with daratumumab (D‐VTd) in CASSIOPEIA versus VTd in PETHEMA/GEM in transplant‐eligible patients with newly diagnosed multiple myeloma, using propensity score matching

P. Sonneveld, P. Moreau, C. D. de Boer, 2020, EJHaem.

Matching‐adjusted indirect comparison of efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) as per label compared with modified VTd dosing schedules in patients with newly diagnosed multiple myeloma who are transplant eligible

P. Sonneveld, P. Moreau, T. Facon, 2020, EJHaem.

Articles and Brief Reports Design and Methods Thalidomide versus Dexamethasone for the Treatment of Relapsed And/or Refractory Multiple Myeloma: Results from Optimum, a Randomized Trial

A. Glasmacher, R. Hájek, H. Avet-Loiseau, 2022 .

Heavy + light chain analysis to assign myeloma response is analogous to the IMWG response criteria

B. Pégourié, O. Decaux, P. Moreau, 2018, Leukemia & lymphoma.

A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial

M. Dimopoulos, J. H. Lee, M. Mohty, 2018, Leukemia.

Initial Phase 3 Results Of The First (Frontline Investigation Of Lenalidomide + Dexamethasone Versus Standard Thalidomide) Trial (MM-020/IFM 07 01) In Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible For Stem Cell Transplantation (SCT)

M. Dimopoulos, J. Cavenagh, A. Dispenzieri, 2013 .

MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs

O. Decaux, A. Lamblin, P. Moreau, 2013, Thrombosis and Haemostasis.

multiple myeloma autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo followed by a dose-reduced allograft (IFM99-03 trial) with tandem Prospective comparison of autologous stem cell transplantation

G. Marit, J. Harousseau, M. Attal, 2013 .

Hevylite® to Monitor Response to Therapy in Multiple Myeloma

B. Pégourié, O. Decaux, P. Moreau, 2014 .

Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma.

I. Yakoub-Agha, M. Mohty, S. Leyvraz, 2008, Blood.

Evaluation of the Prognostic Value of Positron Emission Tomography-Computed Tomography (PET-CT) at Diagnosis and Follow-up in Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients Treated in the Phase 3 Cassiopeia Study: Results of the Cassiopet Companion Study

P. Sonneveld, P. Moreau, X. Leleu, 2019, Blood.

Evaluation of Minimal Residual Disease (MRD) By Next Generation Sequencing (NGS) Is Highly Predictive of Progression Free Survival in the IFM/DFCI 2009 Trial

N. Munshi, P. Richardson, M. Faham, 2015 .

A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial

M. Dimopoulos, M. Mohty, A. Belch, 2019, Leukemia.

Bortezomib‐based therapy for relapsed/refractory multiple myeloma in real‐world medical practice

M. Dimopoulos, A. Belch, E. Katodritou, 2018, European journal of haematology.

Continuous treatment with lenalidomide and low‐dose dexamethasone in transplant‐ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial

J. H. Lee, Zhi-xiang Shen, Kihyun Kim, 2017, British journal of haematology.

Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma.

J. Mary, P. Moreau, H. Avet-Loiseau, 2015, Blood.

Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial

B. Pégourié, P. Cony-Makhoul, O. Decaux, 2015, Haematologica.

Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: Preliminary Results of an IFM Phase II Study

J. Harousseau, V. Coiteux, M. Attal, 2005 .

Comparison of melphalan-prednisone-thalidomide (MP-T) to melphalan-prednisone (MP) in patients 75 years of age or older with untreated multiple myeloma (MM). Preliminary results of the randomized, double-blind, placebo controlled IFM 01–01 trial

B. Pégourié, G. Guillerm, X. Leleu, 2007 .

Major Superiority of Melphalan - Prednisone (MP) + Thalidomide (THAL) over MP and Autologous Stem Cell Transplantation in the Treatment of Newly Diagnosed Elderly Patients with Multiple Myeloma.

Brigitte Pegourie, J. Y. Mary, B. Pégourié, 2005 .

Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.

B. Pégourié, O. Decaux, P. Moreau, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

All-oral triplet combination of ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible multiple myeloma patients: final results of the phase II IFM 2013-06 study

M. Mohty, P. Moreau, X. Leleu, 2022, Haematologica.

Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab plus bortezomib/thalidomide/dexamethasone in the phase III CASSIOPEIA study

P. Sonneveld, P. Moreau, T. Facon, 2021, Haematologica.

Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results

S. Iida, H. Nahi, V. De Stefano, 2020, Journal of Cancer Research and Clinical Oncology.

Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study.

M. Vekemans, P. Moreau, H. Avet-Loiseau, 2022, Blood.

Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials.

P. Fayers, P. Sonneveld, J. Mary, 2011, Blood.

Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients

B. Pégourié, C. Sebban, P. Moreau, 2014, Haematologica.

Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?

M. Mohty, P. Moreau, F. Magrangeas, 2015, Blood.

Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience.

N. Munshi, M. Mohty, P. Moreau, 2015, Blood.

Maintenance Treatment with Thalidomide after Autologous Transplantation for Myeloma : First Analysis of a Prospective Randomized Study of the Intergroupe Francophone du Myelome (IFM 99 02).

B. Coiffier, J. Bourhis, S. Leyvraz, 2004 .

Efficacy and safety profile of long‐term exposure to lenalidomide in patients with recurrent multiple myeloma

X. Leleu, T. Facon, A. Perrot, 2013, Cancer.

Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS

H. Goldschmidt, A. Oriol, P. Moreau, 2023, Blood Cancer Journal.

Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma

R. Hájek, P. Moreau, Kihyun Kim, 2020, Blood advances.

Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination before and after Autologous Stem Cell Transplantation (ASCT) Followed By Ixazomib Maintenance Is a Safe and Effective Strategy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du MyéLome (

P. Moreau, H. Avet-Loiseau, X. Leleu, 2017 .

Subcutaneous Daratumumab Plus Standard Treatment Regimens in Patients with Multiple Myeloma across Lines of Therapy: Pleiades Study Update

S. Iida, C. Touzeau, A. Chari, 2019, Blood.

Phase 3 randomized study of daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) vs VTd in transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 1 results.

P. Sonneveld, M. Béné, P. Moreau, 2019, Journal of Clinical Oncology.

Integrated Analysis of Bortezomib-Lenalidomide-Dexamethasone vs Bortezomib-Thalidomide-Dexamethasone in Transplant-Eligible Newly Diagnosed Myeloma

A. Oriol, P. Moreau, M. Macro, 2019, Clinical Lymphoma Myeloma and Leukemia.

Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination before and after Autologous Stem Cell Transplantation (ASCT) Followed By Ixazomib Maintenance in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du MyéLome (IFM)

M. Béné, P. Moreau, S. Minvielle, 2016 .

Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk

M. Mohty, H. Avet-Loiseau, M. Macro, 2020, Haematologica.

Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death.

H. Goldschmidt, A. Palumbo, P. Sonneveld, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Toxoplasmosis in kidney transplant recipients: report of six cases and review.

L. Frimat, M. Kessler, É. Renoult, 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Impact of free light chain hemodialysis in myeloma cast nephropathy: A case–control study

L. Frimat, C. Hulin, J. Cridlig, 2011, Hemodialysis international. International Symposium on Home Hemodialysis.

Shaji K. Kumar, T. Plesner, R. Orlowski, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Dose-Expansion Phase of the CC-220-MM-001 Trial

S. Jagannath, S. Lonial, P. Richardson, 2021, Blood.

1p22 and 1p32 Deletions Are Independent Prognosis Factors in Young Patients with Myeloma: The IFM Experience On 1195 Patients

B. Pégourié, C. Sebban, P. Moreau, 2012 .

Multiple myeloma: multicenter and multi-professional development of a reference guide on patient's skills

C. Rioufol, I. Madelaine, C. Hulin, 2016 .

Bortezomib retreatment for relapsed and refractory multiple myeloma in real‐world clinical practice

M. Dimopoulos, A. Belch, E. Katodritou, 2018, Health science reports.

Daratumumab carfilzomib lenalidomide and dexamethasone as induction therapy in high-risk, transplant-eligible patients with newly diagnosed myeloma: Results of the phase 2 study IFM 2018-04.

O. Decaux, P. Moreau, H. Avet-Loiseau, 2022, Journal of Clinical Oncology.

Primary Plasma Cell Leukemia displaying t(11;14) have specific genomic, transcriptional and clinical feature.

M. Mohty, H. Avet-Loiseau, M. Macro, 2022, Blood.

EPIDEMIOLOGICAL LANDSCAPE OF YOUNG MULTIPLE MYELOMA PATIENTS DIAGNOSED EARLIER THAN 40 YEARS: THE FRENCH EXPERIENCE.

P. Morel, H. Avet-Loiseau, X. Leleu, 2021, Blood.

Bortezomib (VELCADE®) Plus Dexamethasone as Induction Treatment Prior to Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: Preliminary Results of an IFM Phase II Study.

R. Gressin, X. Leleu, J. Harousseau, 2004 .

Bortezomib and High-Dose Melphalan Vs. High-Dose Melphalan As Conditioning Regimen before Autologous Stem Cell Transplantation in De Novo Multiple Myeloma Patients: A Phase 3 Study of the Intergroupe Francophone Du Myelome (IFM 2014-02)

B. Pégourié, P. Moreau, M. Macro, 2017 .

Impact of Cytogenetics on Outcomes of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone in the First (MM-020) Trial

M. Dimopoulos, A. Belch, D. Reece, 2015 .

Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials

P. Sonneveld, B. Pégourié, M. Boccadoro, 2013, Haematologica.

18F-FDG PET/CT and MRI in the Management of Multiple Myeloma: A Comparative Review

E. Hindié, L. Bordenave, V. Latrabe, 2022, Frontiers in Nuclear Medicine.

Prospective comparison of 18-FDG PET/CT and whole-body diffusion-weighted MRI in the assessment of multiple myeloma

E. Hindié, L. Bordenave, V. Latrabe, 2020, Annals of Hematology.

E. Hindié, L. Bordenave, V. Latrabe, 2020, JMIR research protocols.

Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience.

B. Pégourié, O. Decaux, P. Moreau, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of Chromosomal Abnormalities Del(13), T(4;14), and Del(17p) and Prior Treatment on Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Treated with Lenalidomide

J. Soulier, P. Moreau, T. Facon, 2008 .

Pomalidomide and dexamethasone until progression after first salvage therapy in multiple myeloma

P. Moreau, M. Macro, X. Leleu, 2023, British Journal of Haematology.

Efficacy of bendamustine in relapsed/refractory myeloma patients: results from the French compassionate use program

P. Moreau, G. Marit, G. Damaj, 2012, Leukemia & lymphoma.

Teclistamab in Combination with Subcutaneous Daratumumab and Lenalidomide in Patients with Multiple Myeloma: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study

J. Goldberg, C. Touzeau, C. Hulin, 2022, Blood.

Phase 1 study of the combination of escalated total marrow irradiation using helical Tomotherapy and fixed high-dose melphalan (140 mg/m²) followed by autologous stem cell transplantation at first relapse in multiple myeloma.

P. Maingon, P. Moreau, C. Touzeau, 2022, International journal of radiation oncology, biology, physics.

Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma

M Boccadoro, G. Descamps, M. Amiot, 2011, Leukemia.

Bendamustine, Bortezomib and Dexamethasone (BVD) in Elderly Patients with Multiple Myeloma in First Relapse: Updated Results of the Intergroupe Francophone Du Myelome (IFM) 2009-01 Trial

B. Pégourié, O. Decaux, P. Moreau, 2012 .

Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone

J. Soulier, I. Yakoub-Agha, P. Moreau, 2010, Leukemia.

Phase I/II study of carfilzomib plus melphalan-prednisone (CMP) in elderly patients with de novo multiple myeloma.

P. Moreau, X. Leleu, T. Facon, 2012 .

Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: IFM 2020-04 study.

O. Decaux, P. Moreau, H. Avet-Loiseau, 2023, Haematologica.

Lenalidomide After Autologous Transplantation for Myeloma: First Analysis of a Prospective, Randomized Study of the Intergroupe Francophone Du Myelome (IFM 2005 02).

S. Leyvraz, P. Moreau, H. Avet-Loiseau, 2009 .

Pharmacokinetics (PK) and Pharmacodynamics (PD) of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma: Effects of Subcutaneous Injection Site and Concentration, and Patient Characteristics

D. Esseltine, K. Venkatakrishnan, P. Moreau, 2011 .

Effect of CMP, carfilzomib (CFZ) plus melphalan-prednisone (MP), on response rates in elderly patients (pts) with newly diagnosed multiple myeloma (NDMM): Results of a phase (Ph) I/II trial.

P. Moreau, X. Leleu, C. Touzeau, 2013 .

[Multifocal progressive leukoencephalitis in a patient given fludarabine for chronic lymphoid leukemia].

L. Taillandier, H. Vespignani, R. Anxionnat, 2002, Revue neurologique (Paris).

Bendamustine, bortezomib, and dexamethasone (BVD) in elderly patients with relapsed/refractory multiple myeloma (RRMM): The Intergroupe Francophone du Myélome (IFM) 2009-01 protocol.

B. Pégourié, O. Decaux, P. Moreau, 2012 .

Frontline Therapy with Bortezomib, Lenalidomide, and Dexamethasone (VRD) Induction Followed by Autologous Stem Cell Transplantation, VRD Consolidation and Lenalidomide Maintenance In Newly Diagnosed Multiple Myeloma Patients: Primary Results of the IFM 2008 Phase II Study

B. Pégourié, P. Moreau, H. Avet-Loiseau, 2010 .

Efficacy of isatuximab/pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA-MM high-risk cytogenetics subgroup analysis

P. Richardson, S. Harrison, T. Facon, 2019, Clinical Lymphoma, Myeloma & Leukemia.

Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor.

M. Mohty, H. Avet-Loiseau, M. Macro, 2022, Blood.

Efficacy of Daratumumab, Lenalidomide, and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma and Impaired Renal Function from the Phase 3 Maia Study Based on Lenalidomide Starting Dose

H. Goldschmidt, Shaji K. Kumar, T. Plesner, 2021, Blood.

Carfilzomib Weekly Plus Melphalan and Prednisone in Newly Diagnosed Elderly Multiple Myeloma (IFM 2012-03)

O. Decaux, P. Moreau, X. Leleu, 2015 .

An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT

S. Iacobelli, P. Chevallier, I. Yakoub-Agha, 2023, Bone Marrow Transplantation.

Predictors of Lenalidomide Refractory Relapse Timing With Newly Diagnosed Multiple Myeloma: A FIRST Trial Subanalysis.

M. Dimopoulos, X. Leleu, M. Delforge, 2023, Clinical lymphoma, myeloma & leukemia.

Non-interventional Study Evaluating the Mobilization of Stem Cells by Plerixafor Before Salvage Autologous Stem Cell Transplant in Relapsed Multiple Myeloma (IFM-2015-03)

M. Mohty, P. Moreau, C. Touzeau, 2023, Clinical Hematology International.

Cost-effectiveness of lenalidomide plus dexamethasone vs bortezomib plus melphalan and prednisone in transplant-ineligible US patients with newly-diagnosed multiple myeloma

J. Cavenagh, A. Belch, A. Nooka, 2016, Journal of medical economics.

Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX study

X. Leleu, K. Laribi, V. Richez, 2023, Annals of Hematology.

Real-Life Survival Data after Triple-Exposure to Proteasome Inhibitors (PI), Immunomodulators (IMID) and Anti-CD38 in Multiple Myeloma Patients in the Emmy Cohort

A. Vekhoff, O. Decaux, N. Texier, 2021, Blood.

T. Plesner, H. Nahi, T. Facon, 2022, HemaSphere.

A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide in Frail Patients with Newly-Diagnosed Multiple Myeloma: Efficacy and Safety Analysis of the Phase 3 IFM2017-03 Trial

J. Mary, P. Moreau, H. Avet-Loiseau, 2022, Blood.

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study

H. Goldschmidt, Shaji K. Kumar, T. Plesner, 2022, Blood.

RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study

Meike Schneider, P. Moreau, Sung-Soo Yoon, 2022, Blood.

Subcutaneous (SC) Daratumumab (DARA) in Combination With Standard Multiple Myeloma (MM) Treatment Regimens: An Open-label, Multicenter Phase 2 Study (PLEIADES)

H. Goldschmidt, S. Iida, P. Moreau, 2019, Clinical Lymphoma Myeloma and Leukemia.

Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi‐centre retrospective cohort study

F. Fagnani, P. Moreau, X. Armoiry, 2011, Journal of clinical pharmacy and therapeutics.

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: Updated Analysis of Maia

H. Goldschmidt, Shaji K. Kumar, T. Plesner, 2019, Blood.

Daratumumab Plus Bortezomib, Thalidomide, and Dexamethasone (D-VTd) in Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of High-risk Patients (Pts) in CASSIOPEIA

P. Sonneveld, P. Moreau, X. Leleu, 2019, Clinical Lymphoma Myeloma and Leukemia.

A Matching-Adjusted Indirect Comparison (MAIC) of Daratumumab-Bortezomib-Thalidomide-Dexamethasone (D-VTd) Versus Bortezomib-Lenalidomide-Dexamethasone (VRd) in Patients (Pts) With Newly Diagnosed Multiple Myeloma (NDMM) who are Transplant Eligible

P. Sonneveld, P. Moreau, X. Leleu, 2019, Clinical Lymphoma Myeloma and Leukemia.

S874 EFFICACY OF DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD) IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA BASED ON MINIMAL RESIDUAL DISEASE STATUS: ANALYSIS OF CASSIOPEIA

P. Sonneveld, M. Béné, P. Moreau, 2019, HemaSphere.

PF598 STEM CELL YIELD AND TRANSPLANTATION IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD): PHASE 3 CASSIOPEIA STUDY

P. Sonneveld, P. Moreau, T. Facon, 2019, HemaSphere.

Efficacy of Bortezomib Plus Dexamethasone Versus Bortezomib Monotherapy In Patients with Relapsed/Refractory Multiple Myeloma: An Interim Report from an International Electronic Observational Study

M. Dimopoulos, E. Katodritou, K. Zervas, 2010 .

MELPHALAN-PREDNISONE-THALIDOMIDE (MP-T) DEMONSTRATES A SIGNIFICANT SURVIVAL ADVANTAGE IN ELDERLY PATIENTS >75 YEARS WITH MULTIPLE MYELOMA COMPARED WITH MELPHALAN-PREDNISONE (MP) IN A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, IFM01/01

B. Pégourié, O. Decaux, P. Moreau, 2008 .

Estimating direct costs of care for patients with relapsed or refractory multiple myeloma in french hospitals

F. Fagnani, P. Moreau, X. Armoiry, 2008 .

Trends in Autologous Transplantation for Myeloma in EBMT Centres between 1993 and 2017

J. Gribben, H. Goldschmidt, I. Yakoub-Agha, 2019, Blood.

The Impact of Lenalidomide, Bortezomib, and Dexamethasone Treatment on Health-Related Quality of Life in Transplant-Eligible Patients with Newly-Diagnosed Multiple Myeloma: Results from the IFM/DFCI 2009 Trial

P. Moreau, M. Macro, X. Leleu, 2018, Blood.

Bortezomib, Thalidomide and Dexamethasone (VTD) Is Superior to Bortezomib, Cyclophosphamide and Dexamethasone (VCD) Prior to Autologous Stem Cell Transplantation for Patients with De Novo Multiple Myeloma. Results of the Prospective IFM 2013-04 Trial

B. Pégourié, P. Moreau, H. Avet-Loiseau, 2015 .

Prospective comparison of autologous stem cell transplantation followed by a dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple

I. Yakoub-Agha, G. Marit, J. Harousseau, 2005 .

Carfilzomib PLUS Melphalan and Prednisone (CMP) Is A Promising Combination Therapy For The Treatment Of Elderly Patients With NEWLY Diagnosed Multiple Myeloma: Results Of A PHASE I/II Trial In 68 CASES

P. Moreau, X. Leleu, C. Touzeau, 2013 .

Toxoplasmosis in kidney transplant recipients: a life-threatening but treatable disease.

M. Kessler, É. Renoult, C. Hulin, 1997, Transplantation Proceedings.

J. Bourhis, I. Yakoub-Agha, P. Moreau, 2006, Blood.

Bortezomib-doxorubicin-cyclophosphamide-dexamethasone induction followed by stem cell transplantation for primary plasma cell leukemia: a prospective phase II study of the IFM

P. Moreau, H. Avet-Loiseau, M. Macro, 2016 .

Real-Life-Setting Effectiveness of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma: The Remix Study

N. Texier, M. Macro, X. Leleu, 2020 .

Clinical Trials and Observations

C. Bloomfield, L. Staudt, A. Rosenwald, 2005 .

Long Term Follow-up of Hematopoietic Stem Cell Transplantation (HSCT) for Primary Plasma Cell Leukemia (pPCL): Final Results of a Prospective Study of IFM Group

L. Fornecker, P. Moreau, S. Minvielle, 2016 .

Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma.

B. Pégourié, O. Decaux, M. Mohty, 2016, Blood.

Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.

Sin-Ho Jung, A. Palumbo, P. Richardson, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial.

B. Pégourié, P. Moreau, H. Avet-Loiseau, 2016, Blood.

Transmission of toxoplasmosis by renal transplant: a report of four cases.

M. Kessler, É. Renoult, C. Hulin, 1996, Transplantation proceedings.

P. Moreau, H. Avet-Loiseau, G. Marit, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Daratumumab Carfilzomib Lenalidomide and Dexamethasone with tandem transplant in high-risk newly diagnosed myeloma.

H. Avet-Loiseau, M. Macro, L. Planche, 2024, Blood.

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

M. Boccadoro, R. Mina, E. Katodritou, 2023, The New England journal of medicine.

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study

H. Goldschmidt, Shaji K. Kumar, T. Plesner, 2022, Blood.

Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial

M. Vekemans, M. Macro, C. Touzeau, 2024, The Lancet Oncology.

A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial

M. Dimopoulos, M. Mohty, A. Belch, 2019, Leukemia.

Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy.

B. Pégourié, B. Grosbois, J. Mary, 2006, Blood.

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial.

M. Macro, C. Touzeau, K. Laribi, 2024, Nature medicine.